RBC Cancer Research Results

RBC, Red Blood Cells: Click to Expand ⟱
Source:
Type:

Red Blood Cells
Scientific Papers found: Click to Expand⟱
7133- Ge-132,    Organogermanium, Ge-132, promotes the clearance of senescent red blood cells via macrophage-mediated phagocyte activation
- in-vitro, Nor, RAW264.7
*RBC↑, RBC production is increased to compensate for the amount of degradation, and RBC metabolism is increased.
*antiOx↑, Ingestion of Ge-132 increases fecal antioxidant capacity.

7643- Ins,  IP6,    Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical stud
- Trial, BC, NA
RBC↑, Patients receiving chemotherapy, along with IP6 + Inositol did not have cytopenia, drop in leukocyte and platelet counts.
QoL↑, patients who took IP6 + Inositol had significantly better quality of life
eff↑, combination of IP6 and inositol was significantly better in different cancers (colon, breast and metastatic lung cancer model) than was either one alone
Imm↑, Due to its strong antioxidant activity, and health beneficial effects, such as immune stimulation, prevention of kidney stone formation and hypocholesterolemic effect, IP6 + Inositol is available as dietary supplement.
ChemoSen↑, It has been shown in vitro that IP6 acts synergistically with doxorubicin and tamoxifen
chemoP↑, several case studies have shown that when IP6 and inositol were given in combination with chemotherapy, side effects of chemotherapy were diminished and patients were able to perform their daily activities
Dose↝, recommended prophylactic dosage of IP6 + Inositol is 1-2 g/day and a cancer therapeutic dosage is 8-12 g/day

7640- IP6,  Ins,    Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
- Trial, BC, NA
*antiOx↑, Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-life.
QoL↑,
RBC↑, The Inositol Group showed a lower decrease in red blood cells, hemoglobin levels and white blood cells with respect to controls
HemoG↑,
WBC↑,
chemoP↑, , as well as amelioration in scores related to breast and arm local symptoms (p ≤ 0.02), body image (p = 0.04) and quality-of-life related symptoms
Dose↝, BC patients enrolled in the Inositol Group received topical gel containing 5 g of 4% IP6 and capsules containing 390 mg of myo-inositol


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

RBC↑, 2,   WBC↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

HemoG↑, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 2,   QoL↑, 2,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

RBC↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,  
Total Targets: 2

Scientific Paper Hit Count for: RBC, Red Blood Cells
2 Inositol
2 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
1 Germanium Organic/Ge-132 / propagermanium (organogermanium)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1583  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page